We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Almirall

News List

Allergan divests five dermatology medicines to Almirall for $550m pharmaceutical-technology
August 07, 2018
Allergan has signed a definitive agreement to divest five products under its US Medical Dermatology division to Spanish pharmaceutical company Almirall for a cash consideration of $550m.
Almirall picks up Allergan's dermatology portfolio to for $650m pharmafile
August 06, 2018
Allergan has sealed a deal to sell its dermatology portfolio, comprising five brands, to Spanish pharmaceutical firm Almirall for $650 million in cash.
Almirall buys Allergan's US dermatology portfolio for $650 million pharmatimes
August 06, 2018
Spain’s Almirall has acquired Allergan’s US dermatology portfolio in a deal worth up to $650 million. This includes an upfront cash payment of $550 million and a potential earn-out of up to $100 million payable in 2022 based on the performance of the port
Sanofi veteran Peter Guenter exits top diabetes role to take helm at Almirall fiercepharma
August 30, 2017
The CEO job at Spanish drugmaker Almirall lured Sanofi EVP Peter Guenter away from his role leading the company's diabetes and cardiovascular business.

Previous page 1 2 Next page